US 12,291,798 B2
Generation of binding molecules
Mark Throsby, Utrecht (NL); Ton Logtenberg, Driebergen (NL); and John De Kruif, Bilthoven (NL)
Assigned to Merus N.V., Utrecht (NL)
Filed by Merus N.V., Utrecht (NL)
Filed on Aug. 5, 2022, as Appl. No. 17/817,959.
Application 17/817,959 is a division of application No. 16/852,184, filed on Apr. 17, 2020, granted, now 11,408,095.
Application 16/852,184 is a continuation of application No. 15/821,502, filed on Nov. 22, 2017, granted, now 10,647,781, issued on May 12, 2020.
Application 15/821,502 is a continuation of application No. 14/856,417, filed on Sep. 16, 2015, granted, now 9,908,946, issued on Mar. 6, 2018.
Application 14/856,417 is a continuation of application No. 13/627,381, filed on Sep. 26, 2012, granted, now 9,145,588, issued on Sep. 29, 2015.
Claims priority of provisional application 61/539,116, filed on Sep. 26, 2011.
Prior Publication US 2023/0160105 A1, May 25, 2023
Int. Cl. C40B 50/06 (2006.01); C07K 16/00 (2006.01); C07K 16/10 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C07K 16/46 (2006.01); C12Q 1/6869 (2018.01); C40B 30/04 (2006.01)
CPC C40B 50/06 (2013.01) [C07K 16/00 (2013.01); C07K 16/1018 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); C07K 16/468 (2013.01); C12Q 1/6869 (2013.01); C07K 2317/21 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C40B 30/04 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method for producing a population of antibodies which bind to an antigen, said method comprising:
a) obtaining B cells from lymph nodes, spleen, blood, and bone marrow from a transgenic non-human animal immunized with said antigen;
wherein said transgenic non-human animal expresses a rearranged human antibody light chain variable region (VL) from a VL nucleic acid,
wherein said transgenic non-human animal expresses a human antibody heavy chain variable region (VH) repertoire from a repertoire of VH nucleic acids,
said B cells expressing a repertoire of VHs and a limited immunoglobulin light chain variable (VL) region repertoire,
b) obtaining nucleic acids encoding antibody heavy chain variable (VH) regions from said B cells,
c) obtaining nucleotide sequences of the obtained nucleic acids of step b),
d) determining the frequency of nucleotide sequences from step c) which encode VH regions,
e) providing host cells, wherein each host cell comprises at least one vector comprising a nucleotide sequence encoding at least one VH region having a sequence from those determined in step d) wherein each said host cell expresses the rearranged human VL nucleic acid of step a) and said at least one VH region,
f) culturing said host cells from step e) and allowing for expression of said VL and VH regions, and
g) obtaining said population of antibodies from the cultured host cells of step f) which bind said antigen.